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Antifungal activityAbstract A series of novel compounds N0-(4-(arylamino)-6-(thiazol-2-ylamino)-1,3,5-triazin-2-
yl)isonicotinohydrazides (3al) were synthesized by a series of multistep reactions. Newly synthe-
sized compounds have been characterized by IR, 1H NMR, 13C NMR and mass spectral data.
Antimicrobial screening of title compounds (3al) was examined against Gram-positive bacteria
(Staphylococcus aureus, Streptococcus pyogenes), Gram-negative bacteria (Escherichia coli, Pseudo-
monas aeruginosa) and three fungi (Candida albicans, Aspergillus niger, Aspergillus clavatus) by
using serial broth dilution method. Synthesized compounds showed potent inhibitory action against
test organisms. Screened compounds 3k and 3l were associated with considerably higher antibacte-
rial and antifungal activities than commercially used antibiotics.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Substituted heterocyclic compounds offer a high degree of
structural diversity and have proven to be broadly useful as
therapeutic agents (Krchnak and Holladay, 2002). 1,3,5-Tri-
azine analogs constitute an important class of the realm of het-
erocycles, which has attracted much synthetic interest due to
their wide range of biological activities such as antimicrobial
(Zhou et al., 2008) (Srinivas et al., 2006) (Baliani et al., 2006),
anticancer, (Menicagli et al., 2004) (Garaj et al., 2005),antimalarial (Melato et al., 2008), and antiviral activity (Xiong
et al., 2008). Profound medicinal applications associated with
isonicotinohydrazide render them as useful structural units in
drug research (Maccari et al., 2004). Thiazoles and their deriv-
atives have found applications in drug development for the
treatment of allergies (Hargrave et al., 1983), inﬂammation
(Holla et al., 2003), bacterial infections (Desai et al., 2012a),
HIV infections (Bell et al., 1995) and as new inhibitors of bac-
terial DNA gyrase B (Rudolph et al., 2001). Thiazole nucleus is
also an integral part of all the available penicillins which have
revolutionized the therapy of bacterial diseases (Oncu et al.,
2004). Therefore, it was thought of interest to develop a system
which combines bio-labile nuclei; 1,3,5-Triazine, ison-
icotinohydrazide and thiazole together in a molecular frame-
work to see their additive effect on antimicrobial power.
The toxicity, side effects, and resistance of common patho-
gens to standard drugs play important roles in treatment fail-
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searching for new antimicrobial agents with speciﬁc activity,
possibly acting through mechanism, which are distinct from
those of well-known classes is of prime interest. The above
facts coupled with our desire to develop efﬁcacious antimicro-
bial agents and in continuation of our work on heterocycles
with biological interest (Desai et al., 2012b,c,d,e,f) prompted
us to device an efﬁcient and convenient synthetic method of
hitherto unknown and new title compounds N0-(4-(arylami-
no)-6-(thiazol-2-ylamino)-1,3,5-triazin-2-yl)isonicotinohydraz-
ides (3al). The antibacterial and antifungal results of these
newly synthesized compounds are reported in this paper.
2. Experimental
2.1. Materials and physical measurements
All reactions except those in aqueous media were carried out by
standard techniques for the exclusion ofmoisture.Melting points
were determined on an electro thermal melting point apparatus
and are reported uncorrected. TLC on silica gel plates (Merck,
60, F254) were used for purity checking and reaction monitoring.
Column chromatography on silica gel (Merck, 70–230 mesh and
230–400 mesh ASTH for ﬂash chromatography) was applied
when necessary to isolate and purify the reaction products. Ele-
mental analysis (% C, H, N) was carried out by a Perkin–Elmer
2400 CHN analyzer. IR spectra of all compounds were recorded
on a Perkin–Elmer FT-IR spectrophotometer in KBr. 1H NMR
spectrawere recorded onVarianGemini 300 MHzand 13CNMR
spectra on Varian Mercury-400, 100 MHz in DMSO-d6 as a sol-
vent and tetramethylsilane (TMS) as an internal standard. Mass
spectra were scanned on a Shimadzu LC-MS 2010 spectrometer.
Anhydrous reactions were carried out in oven-dried glassware in
nitrogen atmosphere.
2.2. Preparation of N0-(4,6-dichloro-1,3,5-triazin-2-
yl)isonicotinohydrazide 1
In a conical ﬂask, 2,4,6-trichloro-1,3,5-triazine (0.01 mol) was
taken in 20 mL acetone and isoniazid (i.e. isonicotinohydraz-
ide) (0.01 mol) was added to it. To this mixture, 4% NaOH
was added drop wise at 0–5 C temperature. The solution
was stirred for 2 h. The reaction mixture was then poured onto
crushed ice with constant stirring and neutralized with dilute
HCl. The solid was ﬁltered and washed with water and dried.
The product was recrystallized from acetone. The product was
puriﬁed by column chromatography using hexane–ethyl ace-
tate (4:1) as eluent to get the compound (1). Yield: 75%;
m.p.: 180–182 C; IR (KBr) tmax/cm1: 3340, 3270, 3041,
1716, 1605, 1581, 1517, 767; 1H NMR (300 MHz, DMSO-d6,
d, ppm): 6.57 (s, 1H, –NH-triazine), 7.72–8.87 (m, 4H, Ar–
H), 9.08 (s, 1H, –CONH–); 13C NMR (100 MHz, DMSO-d6,
d, ppm): 121.4, 137.3, 149.3, 164.3, 169.2, 171.8; LC-MS
(m/z): 284 (M+); Anal. Calcd. for C9H6Cl2N6O: C-37.92,
H-2.12, N-29.48; Found: C-37.88, H-2.17, N-29.44%.
2.3. Preparation of N0-(4-chloro-6-(thiazol-2-ylamino)-1,3,5-
triazin-2-yl)isonicotinohydrazide 2
In a conical ﬂask, N0-(4, 6-dichloro-1,3,5-triazin-2-yl)ison-
icotinohydrazide 1 (0.01 mol) was taken in 20 mL acetoneand thiazol-2-amine (0.01 mol) was added to it. To this mix-
ture, 4% NaOH was added drop wise at room temperature
(30 C) and the mixture was stirred for 3 h. The solution was
poured onto crushed ice with constant stirring and neutralized
with dilute HCl. The solid was ﬁltered, washed with water and
dried. The product was recrystallized from ethanol. The prod-
uct was puriﬁed by column chromatography using hexane–
ethyl acetate (4:1) as eluent to get compound 2. Yield: 71%;
m.p.: 235–237 C; IR (KBr) tmax/cm1: 3356, 3320, 3270,
3041, 3010, 1711, 1602, 1582, 1513, 758; 1H NMR (300 MHz,
DMSO-d6, d, ppm): 6.12 (s, 1H, NH-thiazole ring), 6.61 (s,
1H, –NH-triazine), 6.78–8.82 (m, 6H, Ar-H), 9.11 (s, 1H,
–CONH–); 13C NMR (100 MHz, DMSO-d6, d, ppm): 111.5,
121.3, 136.8, 137.3, 149.4, 158.5, 164.2, 165.3, 168.1, 171.2;
LC-MS (m/z): 348 (M+); Anal. Calcd. for C12H9ClN8OS: C-
41.32, H-2.60, N-32.13; Found: C-41.37, H-2.53, N-32.17%.
2.4. Preparation of N0-(4-(arylamino)-6-(thiazol-2-ylamino)-
1,3,5-triazin-2-yl)isonicotinohydrazides 3a-l
In a round bottom ﬂask, N0-(4-chloro-6-(thiazol-2-ylamino)-
1,3,5-triazin-2-yl)isonicotinohydrazide 2 (0.01 mol) and 1,4-
dioxane (20 mL) was taken. To this mixture, different aromatic
amines (0.01 mol) were added. The pH was adjusted to neutral
by adding 8% NaOH and the reaction mixture was reﬂuxed
for 2 h. The reaction mixture was poured onto crushed ice with
constant stirring and was neutralized with dilute HCl. The
product was ﬁltered, washed with cold water and dried. The
product was recrystallized from methanol. The product was
puriﬁed by column chromatography using hexane–ethyl ace-
tate (4:1) as eluent to afford the title compounds.
2.4.1. N0-(4-(phenylamino)-6-(thiazol-2-ylamino)-1,3,5-triazin-
2-yl)isonicotinohydrazide 3a
Yield: 62%; brown crystalline solid; m.p.: 202–204 C; IR (KBr)
tmax/cm
1: 3380, 3350, 3282, 3022, 3010, 1710, 1605, 1589, 1516;
1H NMR (300 MHz, DMSO-d6, d, ppm): 5.64 (s, 1H, –NH-Ar
group), 6.16 (s, 1H,NH-thiazole ring), 6.68 (s, 1H, -NH-triazine),
6.78–8.89 (m, 11H, Ar–H), 9.20 (s, 1H, –CONH–); 13C NMR
(100 MHz, DMSO-d6, d, ppm): 111.7, 117.8, 121.7, 122.4,
129.5, 136.6, 137.7, 138.9, 149.7, 160.1, 163.7, 165.5, 167.9,
171.3; LC-MS (m/z): 405 (M+); Anal. Calcd. for C18H15N9OS:
C-53.32, H-3.73, N-31.09; Found: C-53.37, H-3.78, N-31.14%.
2.4.2. N0-(4-(4-bromophenylamino)-6-(thiazol-2-ylamino)-
1,3,5-triazin-2-yl)isonicotinohydrazide 3b
Yield: 60%; light brown solid; m.p.: 195–197 C; IR (KBr)
tmax/cm
1: 3374, 3352, 3276, 3025, 3017, 1714, 1610, 1582,
1514, 610; 1H NMR (300 MHz, DMSO-d6, d, ppm): 5.69 (s,
1H, -NH-Ar group), 6.13 (s, 1H, NH-thiazole ring), 6.63 (s,
1H, –NH-triazine), 6.71–8.85 (m, 10H, Ar–H), 9.27 (s, 1H,
–CONH–); 13C NMR (100 MHz, DMSO-d6, d, ppm): 111.5,
116.6, 118.7, 121.6, 132.6, 136.7, 137.4, 137.7, 149.6, 160.4,
163.7, 165.5, 167.4, 171.6; LC-MS (m/z): 483 (M+). Anal.
Calcd. for C18H14BrN9OS: C-44.64, H-2.91 N-26.03; Found
C-44.70, H-2.98, N-26.10%.
2.4.3. N0-(4-(2-chlorophenylamino)-6-(thiazol-2-ylamino)-
1,3,5-triazin-2-yl)isonicotinohydrazide 3c
Yield: 65%; light yellow solid; m.p.: 198–200 C; IR (KBr)
tmax/cm
1: 3376, 3356, 3276, 3027, 3015, 1716, 1609, 1586,
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1H, –NH-Ar group), 6.10 (s, 1H, NH-thiazole ring), 6.54
(s, 1H, –NH-triazine), 6.64–8.82 (m, 10H, Ar–H), 9.24 (s,
1H, –CONH–); 13C NMR (100 MHz, DMSO-d6, d, ppm):
111.6, 121.4, 122.6, 122.7, 125.4, 127.4, 130.4, 136.3, 136.7,
137.5, 149.6, 160.4, 163.4, 165.5, 167.6, 171.5; LC-MS (m/z):
439 (M+). Anal. Calcd. for C18H14ClN9OS: C-49.15, H-3.21,
N-28.66; Found C-49.21, H-3.16, N-28.70%.
2.4.4. N0-(4-(3-chlorophenylamino)-6-(thiazol-2-ylamino)-
1,3,5-triazin-2-yl)isonicotinohydrazide 3d
Yield: 61%; yellow crystalline solid; m.p.: 189–190 C; IR
(KBr) tmax/cm
1: 3362, 3350, 3277, 3021, 3010, 1711, 1614,
1584, 1512, 756; 1H NMR (300 MHz, DMSO-d6, d, ppm):
5.64 (s, 1H, –NH-Ar group), 6.10 (s, 1H, NH-thiazole ring),
6.54 (s, 1H, –NH-triazine), 6.64–8.82 (m, 10H, Ar–H), 9.24
(s, 1H, –CONH–); 13C NMR (100 MHz, DMSO-d6, d, ppm):
111.5, 115.4, 116.6, 121.3, 122.7, 130.5, 135.7, 136.5, 137.8,
143.5, 149.4, 160.7, 163.5, 165.7, 167.5, 171.8; LC-MS (m/z):
439.88 (M+); Anal. Calcd. for C18H14ClN9OS: C-49.15, H-
3.21, N-28.66; Found C-49.20, H-3.17, N-28.70%.
2.4.5. N0-(4-(4-chlorophenylamino)-6-(thiazol-2-ylamino)-
1,3,5-triazin-2-yl)isonicotinohydrazide 3e
Yield: 62%; light orange crystalline solid; m.p.: 176–178 C; IR
(KBr) tmax/cm
1: 3376, 3356, 3276, 3027, 3015, 1716, 1609, 1586,
1514, 748; 1H NMR (300MHz, DMSO-d6, d, ppm): 5.60 (s, 1H,
–NH-Ar group), 6.13 (s, 1H, NH-thiazole ring), 6.59 (s, 1H,
–NH-triazine), 6.67–8.80 (m, 10H, Ar–H), 9.28 (s, 1H, –CONH–);
13C NMR (100MHz, DMSO-d6, d, ppm): 111.7, 122.4,
121.6, 127.2, 129.6, 136.3, 137.7, 137.9, 149.3, 160.4, 163.2, 165.7,
167.5, 171.9; LC-MS (m/z): 439 (M+); Anal. Calcd. for
C18H14ClN9OS: C-49.15, H-3.21, N-28.66; Found C-49.23,
H-3.26, N-28.72%.
2.4.6. 2.4.6.N0-(4-(2,5-dichlorophenylamino)-6-(thiazol-2-
ylamino)-1,3,5-triazin-2-yl)isonicotinohydrazide 3f
Yield: 66%; dark brown crystalline solid; m.p.: 199–201 C; IR
(KBr) tmax/cm
1: 3370, 3352, 3266, 3020, 3009, 1714, 1612,
1584, 1510, 754; 1H NMR (300 MHz, DMSO-d6, d, ppm):
5.64 (s, 1H, –NH-Ar group), 6.17 (s, 1H, NH-thiazole ring),
6.58 (s, 1H, –NH-triazine), 6.64–8.83 (m, 9H, Ar-H), 9.33 (s,
1H, -CONH-); 13C NMR (100 MHz, DMSO-d6, d, ppm):
111.4, 118.6, 120.3, 120.6, 121.4, 129.6, 133.2, 136.5, 137.4,
137.8, 149.5, 160.4, 163.5, 165.5, 167.6, 171.5; LC-MS (m/z):
474 (M+); Anal. Calcd. for C18H13Cl2N9OS: C-45.58,
H-2.76, N-26.58; Found C-45.63, H-2.81, N-26.63%.2.4.7. N0-(4-(2,6-dichlorophenylamino)-6-(thiazol-2-
ylamino)1,3,5-triazin-2- yl)isonicotinohydrazide 3g
Yield: 59%; light brown crystalline solid; m.p.: 222–224 C; IR
(KBr) tmax/cm
1: 3373, 3354, 3256, 3031, 3017, 1719, 1611,
1583, 1517, 758; 1H NMR (300 MHz, DMSO-d6, d, ppm):
5.62 (s, 1H, –NH-Ar group), 6.14 (s, 1H, NH-thiazole ring),
6.54 (s, 1H, –NH-triazine), 6.69–8.84 (m, 9H, Ar–H), 9.38 (s,
1H, –CONH–); 13C NMR (100 MHz, DMSO-d6, d, ppm):
111.5, 120.4, 121.7, 128.3, 128.4, 136.6, 136.8, 136.9, 137.5,
138.7, 149.3, 160.5, 163.3, 165.8, 167.4, 171.1; LC-MS
(m/z):474 (M+); Anal. Calcd. for C18H13Cl2N9OS: C-45.58,
H-2.76, N-26.58; Found C-45.62, H-2.80, N-26.62%.2.4.8. N0-(4-(4-ﬂuorophenylamino)-6-(thiazol-2-ylamino)-
1,3,5-triazin-2-yl)isonicotinohydrazide 3h
Yield: 64%; light brown solid; m.p.: 256–258 C; IR (KBr)
tmax/cm
1: 3365, 3352, 3271, 3019, 3010, 1718, 1605, 1584,
1512, 767; 1H NMR (300 MHz, DMSO-d6, d, ppm): 5.60 (s,
1H, –NH-Ar group), 6.13 (s, 1H, NH-thiazole ring), 6.59 (s,
1H, –NH-triazine), 6.67–8.80 (m, 10H, Ar–H), 9.28 (s, 1H,
–CONH–); 13C NMR (100 MHz, DMSO-d6, d, ppm): 111.6,
116.4, 120.5, 121.5, 134.8, 136.3, 137.4, 149.4, 157.6, 160.5,
163.7, 165.4, 167.6, 171.5; LC-MS (m/z): 423 (M+); Anal.
Calcd. for C18H14FN9OS: C-51.06, H-3.33, N-29.77; Found
C-51.11, H-3.40, N-29.82.
2.4.9. N0-(4-(thiazol-2-ylamino)-6-(o-tolylamino)-1,3,5-triazin-
2-yl)isonicotinohydrazide 3i
Yield:61%; yellow crystalline solid, m.p.: 233–235 C; IR (KBr)
tmax/cm
1: 3360, 3345, 3270, 3022, 3014, 1720, 1611, 1583, 1517,
1384; 1H NMR (300 MHz, DMSO-d6, d, ppm): 2.14 (s, 3H,
–CH3), 5.60 (s, 1H, –NH-Ar group), 6.13 (s, 1H, NH-thiazole
ring), 6.59 (s, 1H, –NH-triazine), 6.67–8.80 (m, 10H, Ar–H),
9.28 (s, 1H, –CONH–); 13C NMR (100 MHz, DMSO-d6, d,
ppm): 18.3, 111.4, 121.5, 123.7, 123.8, 126.5, 129.4, 131.5,
136.3, 137.6, 142.7, 149.4, 160.6, 163.4, 165.5, 167.4, 171.7;
LC-MS (m/z): 419 (M+); Anal. Calcd. for C19H17N9OS: C-
54.40, H-4.08, N-30.05; Found C-54.46, H-4.14, N-30.11%.
2.4.10. N0-(4-(thiazol-2-ylamino)-6-(p-tolylamino)-1,3,5-
triazin-2-yl)isonicotinohydrazide 3j
Yield: 64%; off white solid, m.p.: 211–213 C; IR (KBr)
tmax/cm
1: 3373, 3347, 3273, 3024, 3007, 1723, 1614, 1588,
1519, 1390; 1H NMR (300 MHz, DMSO-d6, d, ppm): 2.18 (s,
3H, –CH3), 5.64 (s, 1H, –NH-Ar group), 6.17 (s, 1H, NH-
thiazole ring), 6.54 (s, 1H, –NH-triazine), 6.68–8.80 (m, 10H,
Ar–H), 9.22 (s, 1H, –CONH–); 13C NMR (100 MHz,
DMSO-d6, d, ppm): 21.3, 111.2, 120.5, 121.4, 129.6, 131.4,
135.6, 136.2, 137.5, 149.5, 160.5, 163.6, 165.4, 167.3, 171.6;
LC-MS (m/z): 419 (M+); Anal. Calcd. for C19H17N9OS: C-
54.40, H-4.08, N-30.05; Found C-54.45, H-4.16, N-30.10%.
2.4.11. N0-(4-(2-nitrophenylamino)-6-(thiazol-2-ylamino)-
1,3,5-triazin-2-yl)isonicotinohydrazide 3k
Yield: 65%; yellow solid, m.p.: 221–223 C; IR (KBr)
tmax/cm
1: 3369, 3338, 3270, 3035, 3010, 1720, 1612, 1585,
1512, 1484, 1352; 1H NMR (300 MHz, DMSO-d6, d, ppm):
5.68 (s, 1H, –NH-Ar group), 6.21 (s, 1H, NH-thiazole ring),
6.55 (s, 1H, –NH-triazine), 6.71–8.83 (m, 10H, Ar–H), 9.27
(s, 1H, –CONH–); 13C NMR (100 MHz, DMSO-d6, d, ppm):
110.5, 111.8, 119.3, 121.6, 125.3, 129.5, 136.5, 137.3, 137.6,
144.5, 149.6, 160.1, 163.4, 165.4, 167.9, 171.3; LC-MS (m/z):
450 (M+); Anal. Calcd. for C18H14N10O3S: C-48.00, H-3.13,
N-31.10; Found C-48.06, H-3.08, N-31.06%.2.4.12. N0-(4-(4-nitrophenylamino)-6-(thiazol-2-ylamino)-
1,3,5-triazin-2-yl)isonicotinohydrazide 3l
Yield: 56%;off yellow crystalline solid, m.p.: 233–235 C; IR
(KBr) tmax/cm
1: 3365, 3342, 3275, 3039, 3014, 1722, 1610,
1580, 1510, 1481, 1358; 1H NMR (300 MHz, DMSO-d6, d,
ppm): 5.64 (s, 1H, –NH-Ar group), 6.24 (s, 1H, NH-thiazole
ring), 6.53 (s, 1H, –NH-triazine), 6.73–8.85 (m, 10H, Ar–H),
9.30 (s, 1H, –CONH–); 13C NMR (100 MHz, DMSO-d6, d,
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149.5, 160.3, 163.5, 165.2, 167.2, 171.6; LC-MS (m/z): 450
(M+); Anal. Calcd. for C18H14N10O3S: C-48.00, H-3.13, N-
31.10; Found C-48.08, H-3.18, N-31.17%.
3. Biological screening
3.1. Antibacterial assay
The newly synthesized compounds (3al) were screened for
their antibacterial activity against Gram-positive bacteria S.
aureus (MTCC-96), S. pyogenes (MTCC-442) and Gram-negative
bacteria E. coli (MTCC-443), P. aeruginosa (MTCC-1688). All
MTCC cultures were collected from the Institute of Microbial
Technology, Chandigarh. The activity of compounds was
determined as per the National Committee for Clinical Labo-
ratory Standards (NCCLS) protocol using Mueller Hinton
Broth (Becton Dickinson, USA) (Finegold and Garrod,
1995; Desai et al., 2012f). Compounds were screened for their
antibacterial activity as primary screening in six sets against E.
coli, S. aureus, P. aeruginosa and S. pyogenes at different con-
centrations of 1000, 500 and 250 lg/mL. The compounds
found to be active in primary screening were similarly diluted
to obtain 200, 125, 100, 62.5, 50, 25 and 12.5 lg/mL concentra-
tions for secondary screening to test in a second set of dilution
against all microorganisms. Inoculum size for test strain was
adjusted to 106 CFU/mL (Colony Forming Unit per milliliter)
by comparing the turbidity (turbidimetric method). Mueller
Hinton Broth was used as nutrient medium to grow and dilute
the compound suspension for test bacteria. Two percent
DMSO was used as a diluent/vehicle to obtain the desired con-
centration of synthesized compounds and standard drugs to
test upon standard microbial strains. Synthesized compounds
were diluted to 1000 lg/mL concentration, as a stock solution.
The control tube containing no antibiotic was immediately
subcultured [before inoculation] by spreading a loopful evenly
over a quarter of the plate of medium suitable for the growth
of test organisms. The tubes were then put for incubation at
37 C for 24 h for bacteria. Ten micrograms per milliliter
suspensions was further inoculated on an appropriate media
and growth was noted after 24 h and 48 h. The highest dilution
(lowest concentration) preventing appearance of turbidity was
considered as minimum inhibitory concentration (MIC, lg/
mL) i.e. the amount of growth from the control tube before
incubation (which represents the original inoculum) was
compared. A set of tubes containing only seeded broth and sol-
vent controls were maintained under identical conditions so as
to make sure that the solvent had no inﬂuence on strain
growth. The result of this is greatly affected by the size of
inoculum. The test mixture should contain 106 CFU/mL
organisms. DMSO and sterilized distilled water were used as
negative control while ciproﬂoxacin antibiotic (1 U strength)
was used as positive control. Standard drug used in the present
study was Ciproﬂoxacin for evaluating antibacterial activity
which showed 25, 25, 50 and 50 lg/mL MIC against E. coli,
P. aeruginosa, S. aureus and S. pyogenes, respectively.
3.2. Antifungal assay
The same compounds (3al) were tested for antifungal activity
as primary screening in six sets against C. albicans, A. nigerand A. clavatus at various concentrations of 1000, 500 and
250 lg/mL. The compounds found to be active in primary
screening were similarly diluted to obtain 200, 125, 100, 62.5,
50, 25 and 12.5 lg/mL concentrations for secondary screening
to test in a second set of dilution against all microorganisms.
Griseofulvin was used as a standard drug for antifungal
activity, which showed 500, 100 and 100 lg/mL MIC against
C. albicans, A. niger and A. clavatus, respectively. DMSO and
sterilized distilled water were used as negative control while
griseofulvin (1 U strength) was used as positive control. For
fungal growth, in the present protocol, we have used Sabou-
rauds dextrose broth at 28 C in an aerobic condition for 48 h.
3.3. Statistical analysis
Standard deviation value was expressed in terms of ±SD. On
the basis of calculated value by using the one-way ANOVA
method followed by independent two sample t test, it was ob-
served that differences below 0.001 level were considered statis-
tically signiﬁcant. Compounds (3al) were screened for their
antibacterial and antifungal activities in six sets (n) against
bacteria and fungi used in the present protocol.
4. Results and discussion
4.1. Chemistry
The synthetic pathways to obtain intermediate and ﬁnal com-
pounds are shown in reaction scheme 1. The starting material
1,3,5-trichloro triazine in acetone was reacted with isoniazid
(i.e. isonicotinohydrazide) at 0–5 C temperature in the presence
of NaOHwith constant stirring for 2 h, to produce intermediate
compound (1) i.e. N’-(4, 6-dichloro-1,3,5-triazin-2-yl)ison-
icotinohydrazide in good yield. The intermediate compound
(1) N’-(4, 6-dichloro-1,3,5-triazin-2-yl)isonicotinohydrazide is
found to have spectral evaluation, like IR showed absorption
bands at 3340, 3270, 3041 and 1716 cm1. The 1H NMR in d
ppm showed, as a singlet at 6.57 due to 1H of –NH-triazinemoi-
ety, a multiplet at 7.72–8.87 for 4H of the aromatic ring and a
singlet at 9.08 for 1H of –CONH-linkage. The 13C NMR in
d ppm showed signals at 121.4, 137.3, 149.3, 164.3, 169.2, and
171.8. Moreover, the mass spectrum of (1) showed a molecular
ion peak at (m/z) = 284 (M+) corresponding to molecular for-
mula C9H6Cl2N6O. Compound (1) in acetone was reacted with
thiazol-2-amine at room temperature (30 C) in the presence of
NaOH with constant stirring for 3 h to yield intermediate
compound (2) i.e. N’-(4-chloro-6-(thiazol-2-ylamino)-1,3,5-
triazin-2-yl)isonicotinohydrazide. The intermediate compound
(2) i.e. N’-(4-chloro-6-(thiazol-2-ylamino)-1,3,5-triazin-2-yl)-
isonicotinohydrazide is found to have spectral evaluation, like
IR showed absorption bands at 3356, 3320, 3270, 3041, 3010
and 1711 cm1. The 1H NMR in d ppm showed, a singlet at
6.12 for 1H of –NH-of the thiazole ring, a singlet at 6.61 for
1H of –NH-of triazine part, a multiplet at 6.78–8.82 for 6H of
aromatic character and a singlet at 9.11 for 1H of –CONH-link-
age of compound (2). The 13CNMR in d ppm showed signals at
111.5, 121.3, 136.8, 137.3, 149.4, 158.5, 164.2, 165.3, 168.1 and
171.2. Moreover, the mass spectrum of (2) showed a molecular
ion peak at (m/z) = 348 (M+) corresponding to molecular for-
mula C12H9ClN8OS. In the ﬁnal step, intermediate compound
(2) was reﬂuxed in 1,4-dioxane with different substituted
Scheme 1 Synthetic route for the ﬁnal compounds 3a–l.
S338 N.C. Desai et al.aromatic amines in the presence of NaOH to yield compounds
N’-(4-(arylamino)-6-(thiazol-2-ylamino)-1,3,5-triazin-2-yl)
isonicotinohydrazides (3al). In the ﬁnal step intermediate
compound (2) was reﬂuxed in 1,4-dioxane with aniline in the
presence of NaOH to yield compound (3a) i.e. N’-(4-(phenyla-
mino)-6-(thiazol-2-ylamino)-1,3,5-triazin-2-yl)isonicotinohyd-
razide. Compound (3a) is found to have spectral evaluation, like
IR showed absorption bands at 3380, 3350, 3282, 3022, 3010 and
1710 cm1. The 1H NMR in d ppm showed, singlet at 5.64 for
1H of –NH–Ar, a singlet at 6.16 for 1H of –NH-thiazole ring,
a singlet at 6.68 for 1H,of –NH-triazine, a multiplet at 6.78–
8.89 for 11H of aromatic hydrogens and a singlet at 9.20 for
1H of –CONH-linkage of compound (3a). The 13C NMR of
compound (3a) showed absorption in d ppm at 111.7, 117.8,
121.7, 122.4, 129.5, 136.6, 137.7, 138.9, 149.7, 160.1, 163.7,
165.5, 167.9, and 171.3. Moreover, the mass spectrum of (3a)
showed a molecular ion peak at (m/z) = 405 (M+) correspond-
ing to molecular formula C18H15N9OS.
4.2. Antimicrobial activity
All the newly synthesized compounds were evaluated against
Gram-positive bacteria (S. aureus, S. pyogenes), Gram-
negative bacteria (E. coli, P. aeruginosa) and fungi (Candida
albicans, Aspergillus niger and Aspergillus clavatus) strains.
Individual minimum inhibitory concentration (MIC, lg/mL)
values of tested compounds (3al) against the test microbes
are listed in Table 1 along with MIC values of reference com-
pounds Ciproﬂoxacin (for bacteria) and Griseofulvin (for fun-
gi). Results revealed that majority of synthesized compoundsshowed varying degrees of inhibition against the test panel of
species. The obtained antimicrobial activity of tested
compounds could be correlated to structural variations and
modiﬁcations of the respective compounds. Key precursor,
compound (1) showed poor antibacterial activity. Compound
(2) displayed mild antibacterial activity at MIC 500 lg/mL
against tested bacterial species. Final compounds (3al) exhib-
ited varying degrees of activity against different microbial
strains. Compounds 3k (2-NO2) and 3l (4-NO2) showed highest
inhibition at MIC 12.5 and 25 lg/mL while compounds 3f (2,5-
(Cl)2) and 3h (4-F) displayed a signiﬁcant activity at MIC
50 lg/mL against E. coli. Compounds 3k (2-NO2) and 3l (4-
NO2) showed highest inhibition at MIC 25 and 12.5 lg/mL,
respectively whereas, compounds 3b (4-Br) and 3g (2,6-(Cl)2)
showed a very good activity at MIC 50 lg/mL against P. aeru-
ginosa. Compounds 3h (4-F) and 3k (2-NO2) displayed pro-
nounced activity at MIC 50 lg/mL against S. aureus.
Similarly compound 3k (2-NO2) exhibited highest inhibition
MIC 25 lg/mL while 3f (2,5-(Cl)2), 3h (4-F), 3l (4-NO2) showed
signiﬁcant inhibition at MIC 50 lg/mL against S. pyogenes.
MIC values of antifungal activity exhibited a similar trend
as antibacterial activity. Intermediate (2) showed poor inhibi-
tory effect against all fungal strains (MICP 1000 lg/mL).
Formation of ﬁnal compounds (3al) is found to possess a
broad spectrum of antifungal activity. Among tested com-
pounds, 3k (2-NO2) showed excellent inhibition at MIC
25 lg/mL whereas 3f (2,5-(Cl)2) and 3l (4-NO2) exhibited very
good inhibition at MIC 50 lg/mL against C. albicans.
Compound 3l (4-NO2) showed excellent inhibition at MIC
25 lg/mL while 3e (4-Cl), 3h (4-F) and 3k (2-NO2) exhibited
Table 1 Results of antibacterial and antifungal screening of compounds 3al.
Compounds –R Minimum inhibitory concentration (MIC) for bacteria ug/mL ± SD Minimum inhibitory concentration (MIC) for fungi ug/mL± SD
Gram negative Gram positive
E. coli P. aeruginosa S. aureus S. pyogenes C. albicans A. niger A. clavatus
MTCC-443 MTCC-1688 MTCC-96 MTCC-442 MTCC-227 MTCC-282 MTCC-1323
3a –H 250 ± 2* 500 ± 2.54* 250 ± 3.64* 250 ± 3.54* 500 ± 4.36 500 ± 2.21* 1000 ± 4
3b –4-Br 100 ± 3.05* 50 ± 1.95* 100 ± 4.45 250 ± 3* 250 ± 3 250 ± 2.02* 500 ± 3.26*
3c –2-C1 250 ± 3.45* 500 ± 2* 500 ± 2.23* 100 ± 2.23* 500 ± 3.54* 250 ± 3* 1000 ± 3.23
3d –3-C1 100 ± 1.23** 100 ± 4.50* 100 ± 3** 100 ± 2* 100 ± 2* 100 ± 3.54* 500 ± 3
3e –4-C1 100 ± 4 250 ± 2* 100 ± 2.22* 100 ± 3.12* 100 ± 1.23** 50 ± 3* 250 ± 3.46
3f –2,5-(Cl)2 50 ± 2.35
* 100 ± 3.24* 100 ± 1.34 50 ± 2.4 50 ± 2.27* 100 ± 3* 1000 ± 3.21
3g –2,6-(Cl)2 100 ± 3
* 50 ± 2* 100 ± 4.25 100 ± 3.0* 100 ± 3* 100 ± 2.25 250 ± 2.36
3h –4-F 50 ± 3.05 100 ± 3.12** 50 ± 3* 50 ± 2.3* 100 ± 3.12 50 ± 3.43 100 ± 3.35
3i –2-CH3 250 ± 4
* 500 ± 2* 250 ± 3* 500 ± 3.5* 500 ± 2.26* 500 ± 3.53 1000 ± 4.12
3j –4-CH3 500 ± 1.2
*** 250 ± 2* 500 ± 2.24 250 ± 3.2* 500 ± 2.25* 250 ± 3.54* 500 ± 3.47*
3 k –2-NO2 12.5 ± 3.12
* 25 ± 2.34* 50 ± 3* 25 ± 4.1 25 ± 3.5 50 ± 3.55 25 ± 3.3
31 –4-NO2 25 ± 1.2
*** 12.5 ± 2* 100 ± 2.24 50 ± 3.2* 50 ± 2.25* 25 ± 3.54* 50 ± 3.47*
Ciproﬂoxacin 25 ± 4.57* 25 ± 4.12* 50 ± 4.15* 50 ± 3.55* – – –
Griseofulvin – – – – 500 ± 2.64* 100 ± 3* 100 ± 3.46*
±SD= Standard deviation.
* P< 0.05 signiﬁcant. All values are presented as mean of 6 experiments (n= 6). All signiﬁcant differences are considered from control value 0.00. 2 % DMSO used as control and its antimicrobial
activity is nil or zero.
** P < 0.01 moderately signiﬁcant. All values are presented as mean of 6 experiments (n = 6). All signiﬁcant differences are considered from control value 0.00. 2 % DMSO used as control and its
antimicrobial activity is nil or zero.
*** P < 0.001 extremely signiﬁcant. All values are presented as mean of 6 experiments (n= 6). All signiﬁcant differences are considered from control value 0.00. 2 % DMSO used as control and its
antimicrobial activity is nil or zero.
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S340 N.C. Desai et al.very good inhibition at MIC 50 lg/mL against A. niger.
Compounds 3k (2-NO2) and 3l (4-NO2) exhibited excellent
inhibition at MIC 25 and 50 lg/mL, respectively against
A. clavatus.
4.3. SAR (Structure activity relationship)
On the basis of structure–activity relationship (SAR) studies, the
results suggested that the antimicrobial activity of triazine deriv-
atives was markedly inﬂuenced by various substituents on the
benzene ring and the incorporation of the electron withdrawing
group caused enhancement in activity against most test microor-
ganisms. On the basis of MIC value, it is our observation that
compounds 3h, 3k and 3l possessing electron-withdrawing sub-
stituents (F and NO2) on aromatic ring are more active against
all tested panel of bacteria and fungi than compounds having
electron-donating groups. Notably, compounds 3k and 3l
showed highest inhibition against bacterial strains E. coli and
P. aeruginosa, respectively at MIC 12.5 lg/mL. Furthermore,
compound 3k showed signiﬁcant inhibition against fungi strains
C. albicans andA. clavatus, whereas 3l showed inhibition atMIC
25 lg/mL against A. niger. For such a bio active compound, an
optimum electron density is inevitable (e.g. presence of electron
withdrawing -NO2 group, 3k and 3l) so as to gain a signiﬁcant
antimicrobial activity. It is a very well-known fact that halogen
atom ﬂuoro is hydrophobic in nature; due to this reason, it will
inﬂuence as substituent group’s physicochemical properties on
the activity of compounds. This property is useful to a compound
to diffuse through the biologic membranes and reach to its site of
action. Owing to this reason, hydrophobicity was found to be di-
rectly related to antimicrobial activity. The presence of hydro-
phobic substituent at 4th (i.e.-F, 3h) position of phenyl ring
provides a positive inﬂuence on antimicrobial activity. From
theMICvalueofbiological activity,wemay conclude that, to fur-
nish the most potent antimicrobial agents, compoundsmust con-
tain an electron withdrawing atom/group preferably ﬂuoro and
nitro group as substituent. All other compounds showed good
tomoderate potency. Therefore the electron withdrawing groups
induced a positive effect and the electron donating groups in-
duced a negative effect on the antimicrobial activity.5. Conclusion
The preliminary in vitro antibacterial and antifungal screening
results of new 1,3,5-triazine-isonicotino hydrazide based thia-
zole derivatives exhibited a remarkable antimicrobial potency.
The newly synthesized compounds presented hereby signiﬁ-
cantly differ in their corresponding antimicrobial activity
depending on the type of substituents. In the course of this
study, particularly derivatives possessing electron withdrawing
groups such as ﬂuoro and nitro were identiﬁed as exhibiting po-
tent groups for antimicrobial activity against testedmicroorgan-
isms. It may be concluded that ﬂuoro and nitro substituent
bearing derivatives are the most suitable compounds for
achieving the best antimicrobial spectrum. Thus, it may be con-
sidered as a promising lead for further design and development
of new chemical entities. The results described here, demand fur-
ther investigations in our laboratory using a forward chemical
genetic approach for ﬁnding lead molecules as antimicrobial
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